InvestorsHub Logo
Followers 6
Posts 1087
Boards Moderated 0
Alias Born 07/18/2006

Re: None

Wednesday, 05/29/2019 6:28:01 PM

Wednesday, May 29, 2019 6:28:01 PM

Post# of 17432
The biggest competitive threat Aurinia is concerned about is not Kezar- it's the Benlysta (Belimumab) P3 for LN that will end about the same time as Aurinia's AURORA P3.

"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis (BLISS-LN)"

https://clinicaltrials.gov/ct2/show/NCT01639339?term=Belimumab&recrs=d&phase=2&rank=1

New CEO Peter Greenleaf revealed that May 22 during the RBC Capital Markets 2019 Healthcare Conference webcast.

If you haven't heard it yet, you can at:

https://ir.auriniapharma.com/ir-calendar/detail/1182/rbc-capital-markets-global-healthcare-conference

There is a lot of real meat (both revealed and hinted at) in it regarding Aurinia's plans going forward.

They are really confident.





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News